Aquatic Exercise for Cognition and Mobility in Older Adults

February 27, 2023 updated by: Emily Dunlap

Effects of Aquatic Integrated Cognitive Motor Training on Cognition and Mobility in Older Adults

The purpose of this study is to assess the effects of an aquatic exercise program on cognition and physical function of older adults.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Austin, Texas, United States, 78712
        • The University of Texas at Austin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Able to ambulate 100 ft independently with or without assistive device
  • Score greater than or equal to 3 on the Mini-Cog Test
  • Stable medical condition within one month prior to the study
  • Stable exercise program within one month prior to the study
  • Available during study testing and group class times
  • COVID-19 vaccination
  • Permission from medical provider to participate in the study

Exclusion Criteria:

  • History of dementia or Alzheimer's
  • Contraindication to exercise or pool immersion (e.g., unstable cardiovascular conditions, fever, diarrhea, aqua-phobia)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Aquatic Exercise Group
Aquatic class 45 minutes, 3 times a week, for 8 weeks
Behavioral: Aquatic Integrated Cognitive Motor Training
Aquatic exercise class with focus on cognitive and physical exercise
No Intervention: Control Group
Usual care for 8 weeks and one hour education session on fall prevention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stroop Effect Test: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
Measure of working memory and attention
Measures taken at baseline and again at approximately 9-10 weeks
Trail Making Test A and B: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
Measure of visual scanning and working memory
Measures taken at baseline and again at approximately 9-10 weeks
Digit Backwards Test : Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
Measure of working memory capacity
Measures taken at baseline and again at approximately 9-10 weeks
Gait Measurements: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
4 gait conditions (single task gait, dual task gait with head turns, dual task gait with head nods, and dual task gait count backwards by serial 7s). Gait measures collected with Strideway Gait Analysis System.
Measures taken at baseline and again at approximately 9-10 weeks
Functional Outcome Measures: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
Timed Up and Go Test, Cognitive Timed Up and Go Test, Single Leg Balance Test, and Four Square Step Test.
Measures taken at baseline and again at approximately 9-10 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vital Sign measurements: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
Blood pressure and heart rate taken after 5 min supine, immediately upon standing, and 2 min after standing
Measures taken at baseline and again at approximately 9-10 weeks
Anthropometric measurements: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
Height and weight
Measures taken at baseline and again at approximately 9-10 weeks
Neurotrophic Growth Factors: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
Serum concentration of brain derived neurotrophic factor and insulin-like growth factor 1
Measures taken at baseline and again at approximately 9-10 weeks
Numeric Pain Rating Scale: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
An 11 point scale for level of pain from 0 (no pain) to 10 (severe pain).
Measures taken at baseline and again at approximately 9-10 weeks
Global Rating of Change Questionnaire: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
A 15 point global rating scale for changes in domains, from -7 (a great deal worse); through 0 (no change) to +7 (a great deal better).
Measures taken at baseline and again at approximately 9-10 weeks
Activities-specific balance confidence scale: Change from baseline to the end of intervention/control period
Time Frame: Measures taken at baseline and again at approximately 9-10 weeks
A structured questionnaire that measures an individuals confidence performing daily activities. The minimum score is 0% (no confidence in balance) to 100% (complete confidence in balance).
Measures taken at baseline and again at approximately 9-10 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Emily Dunlap

Investigators

  • Principal Investigator: Emily Dunlap, BS, The University of Texas at Austin

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2022

Primary Completion (Actual)

December 12, 2022

Study Completion (Actual)

December 12, 2022

Study Registration Dates

First Submitted

August 10, 2022

First Submitted That Met QC Criteria

August 11, 2022

First Posted (Actual)

August 15, 2022

Study Record Updates

Last Update Posted (Actual)

March 1, 2023

Last Update Submitted That Met QC Criteria

February 27, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00001403

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Sharing of deidentified individual participant data will be available upon reasonable request.

IPD Sharing Time Frame

The data will become available after publication

IPD Sharing Access Criteria

Data will be available to researcher for meta-analysis purpose upon reasonable request.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Change

Clinical Trials on Aquatic Integrated Cognitive Motor Training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe